Evidence map›Paper›PMID 32863157›Full record

ReviewArchives of cardiovascular diseases

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.

Bernard I Lévy, Jean-Pierre Fauvel, Société Française d’Hypertension Artérielle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bernard I LévyInserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris, France. Electronic address: bernard.levy@inserm.fr.
Jean-Pierre FauvelService de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon, France.
Société Française d’Hypertension Artérielle

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2, which is responsible for the current coronavirus disease 2019 pandemic, uses angiotensin-converting enzyme 2 as a gateway into host cells. In this review, we summarise the biology of this enzyme, which plays a key role in cardiovascular homeostasis. Blockers of the renin-angiotensin system modify the expression and activity of angiotensin-converting enzyme 2 in different ways. The effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the expression and enzyme activity of angiotensin-converting enzyme 2 are reviewed, and the consequences of these treatments for the severity of coronavirus disease 2019 infection are discussed.

Indexed as

BetacoronavirusPandemicsAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersCoronavirus InfectionsCOVID-19HumansPneumonia, ViralRenin-Angiotensin SystemSARS-CoV-2Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin-converting enzyme inhibitorsAngiotensin receptor blockersArterial hypertensionBloqueur des récepteurs de l’angiotensineHeart failureHypertension artérielleInhibiteurs de l’enzyme de conversion de l’angiotensineInsuffisance cardiaque

Identifiers

PMID32863157
PMCPMC7430243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.